...
首页> 外文期刊>Retrovirology >Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
【24h】

Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors

机译:HIV-1蛋白酶的非活性位点突变体对蛋白酶抑制剂的影响性和敏化

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND:HIV-1 can develop resistance to antiretroviral drugs, mainly through mutations within the target regions of the drugs. In HIV-1 protease, a majority of resistance-associated mutations that develop in response to therapy with protease inhibitors are found in the protease's active site that serves also as a binding pocket for the protease inhibitors, thus directly impacting the protease-inhibitor interactions. Some resistance-associated mutations, however, are found in more distant regions, and the exact mechanisms how these mutations affect protease-inhibitor interactions are unclear. Furthermore, some of these mutations, e.g. N88S and L76V, do not only induce resistance to the currently administered drugs, but contrarily induce sensitivity towards other drugs. In this study, mutations N88S and L76V, along with three other resistance-associated mutations, M46I, I50L, and I84V, are analysed by means of molecular dynamics simulations to investigate their role in complexes of the protease with different inhibitors and in different background sequence contexts.RESULTS:Using these simulations for alchemical calculations to estimate the effects of mutations M46I, I50L, I84V, N88S, and L76V on binding free energies shows they are in general in line with the mutations' effect on [Formula: see text] values. For the primary mutation L76V, however, the presence of a background mutation M46I in our analysis influences whether the unfavourable effect of L76V on inhibitor binding is sufficient to outweigh the accompanying reduction in catalytic activity of the protease. Finally, we show that L76V and N88S changes the hydrogen bond stability of these residues with residues D30/K45 and D30/T31/T74, respectively.CONCLUSIONS:We demonstrate that estimating the effect of both binding pocket and distant mutations on inhibitor binding free energy using alchemical calculations can reproduce their effect on the experimentally measured [Formula: see text] values. We show that distant site mutations L76V and N88S affect the hydrogen bond network in the protease's active site, which offers an explanation for the indirect effect of these mutations on inhibitor binding. This work thus provides valuable insights on interplay between primary and background mutations and mechanisms how they affect inhibitor binding.
机译:背景:HIV-1可以产生对抗逆转录病毒药物的抵抗力,主要是通过药物靶区域内的突变。在HIV-1蛋白酶中,在蛋白酶的活性位点中发现了响应于蛋白酶抑制剂的治疗的大多数抗性相关突变,其也是用于蛋白酶抑制剂的结合口袋,从而直接影响蛋白酶抑制剂相互作用。然而,一些抗性相关的突变在更远的区域中发现,并且这些突变如何影响蛋白酶抑制剂相互作用的确切机制尚不清楚。此外,其中一些突变,例如, N88S和L76V,不仅诱导对目前给药的药物的抵抗力,而且对其他药物进行了相反的敏感性。在该研究中,通过分子动力学模拟分析突变N88S和L76V以及三种其他抗性相关突变,M46i,I50L和I84V,以研究其在蛋白酶与不同抑制剂和不同背景序列中的复合物中的作用上下文:使用这些模拟用于炼金术计算来估计突变M46i,I50L,I84V,N88S和L76V的效果的效果显示它们一般符合对[公式:参见文本]值的突变的影响。然而,对于初级突变L76V,在我们的分析中存在背景突变M46i的存在影响L76V对抑制剂结合的不利影响是否足以超过蛋白酶催化活性的伴随降低。最后,我们表明L76V和N88S分别将这些残留物的氢键稳定性与残留物D30 / K45和D30 / T31 / T74改变。结论:我们证明估计结合口袋和远处突变对抑制剂的抑制剂的作用使用炼金术计算可以再现它们对实验测量的[公式:参见文本]值的影响。我们表明远处的位点突变L76V和N88S影响蛋白酶活性位点中的氢键网络,其提供了对这些突变对抑制剂结合的间接影响的解释。因此,这项工作提供了对初级和背景突变之间的相互作用和机制如何影响抑制剂结合的有价值的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号